Pidolic Acid

Pidolic Acid

SCHEMBL223918

O=C1CC[C@H](C(=O)O)N1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Pidolic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pidolic Acid SCHEMBL1239532 1.00 CAD (0.46)
Pidolic Acid SCHEMBL29479230 1.00
Pidolic Acid SCHEMBL10937920 1.00 CAD (0.46)
Pidolic Acid SCHEMBL15791 1.00
Pidolic Acid SCHEMBL152441 1.00 CAD (0.46)
Pidolic Acid SCHEMBL15790 1.00
Pidolic Acid SCHEMBL7554345 1.00 CAD (0.46)
Pidolic Acid SCHEMBL30872192 0.98 CAD (0.44)
Pidolic Acid SCHEMBL10875923 0.98 CAD (0.44)
Pidolic Acid SCHEMBL21693635 0.98 CAD (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1580 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119936394-B Diagnostic system for abdominal aortic aneurysm and application thereof BEIJING FRIENDSHIP HOSPITAL, CAPITAL MEDICAL UNIVERSITY (CN) 2026-05-26 CN claimed
US-12630520-B2 Left-handed bicyclic morpholine and salt thereof, preparation method therefor, pharmaceutical composition, and use INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2026-05-19 US claimed
EP-4709401-A1 ORAL DELIVERY OF PLANT DERIVED VESICLES AND USES THEREOF Board of Regents, The University of Texas System (US) 2026-03-18 EP claimed
WO-2025264604-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME THE PROCTER & GAMBLE COMPANY (US) 2025-12-26 WO claimed
US-12503449-B2 Methods of preparing chiral benzodiazepinone derivatives IMMUNOME, INC. (US) 2025-12-23 US claimed
US-20250381110-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME PROCTER & GAMBLE (US) 2025-12-18 US claimed
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
EP-3606525-B1 COMPOSITIONS FOR TREATING AGING-ASSOCIATED IMPAIRMENTS USING CCR3-INHIBITORS ALKAHEST INC (US) 2025-12-10 EP claimed
US-12473251-B2 Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-11-18 US claimed
US-20250346565-A1 METHODS OF PREPARING CHIRAL BENZODIAZEPINONE DERIVATIVES AYALA PHARMACEUTICALS INC. 2025-11-13 US claimed
EP-0768309-A1 Process for the preparation of enantiomerically pure imidazolyl compounds DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1997-04-16 EP claimed
US-5618948-A TREATMENT OF 6-CARBOXAMIDO-3-METHYLAMINO-1,2,3,4-TETRAHYDROCARBAZOLE WITH 2-PYRROLIDONE-5-CARBOXYLIC ACID, CRYSTALLIZATION SMITHKLINE BEECHAM P.L.C. (GB) 1997-04-08 US claimed
US-5508385-A PROTEASE INHIBITOR; ANTIULCER AGENTS, ANTIINFLAMMATORY AGENTS; TREATING PANCREATITIS NITTO BOSEKI CO., LTD. (JP) 1996-04-16 US claimed
EP-0444482-B1 Oxetanones HOFFMANN LA ROCHE (CH) 1996-01-17 EP claimed
EP-0436005-B1 LABELED POLYPEPTIDE DERIVATIVES SANDOZ LTD (CH) 1995-03-29 EP claimed
EP-0436005-A1 LABELED POLYPEPTIDE DERIVATIVES. SANDOZ LTD (CH) 1991-07-10 EP claimed
WO-1991001144-A1 LABELED POLYPEPTIDE DERIVATIVES SANDOZ LTD (CH) 1991-02-07 WO claimed
WO-1989009786-A1 PEPTIDE DERIVATIVES SANDOZ AG (CH) 1989-10-19 WO claimed
WO-1988002756-A2 PEPTIDE DERIVATIVES SANDOZ AG (CH) 1988-04-21 WO claimed
US-4575509-A AMSACRINE BRISTOL-MYERS COMPANY (US) 1986-03-11 US claimed